In vitro Activity of Quinupristin/ Dalfopristin, RP59500, against Gram-Positive Clinical Isolates
- 1 January 1997
- journal article
- research article
- Published by S. Karger AG in Chemotherapy
- Vol. 43 (2) , 94-99
- https://doi.org/10.1159/000239542
Abstract
SynercidTM (quinupristin/dalfopristin, RP59500) is a new water-soluble streptogramin which offers some advantages over the commercially available antimicrobials against drug-resistant gram-positive bacteria. Its in vitro activity was compared with ampicillin, augmentin, penicillin, erythromycin, oxacillin and vancomycin against gram-positive bacteria isolated from clinical specimens. Of the 837 gram-positive bacteria tested 834 (99.6%) were inhibited by < 0.6–4.0 mg/l of Synercid. It had excellent activity against both staphylococci and streptococci, including methicillin-resistant staphylococci and vancomycin-resistant enterococci.Keywords
This publication has 0 references indexed in Scilit: